Fresenius SE & Co KGaA (Fresenius) focuses on hospital operations. It provides products and services for dialysis, hospitals, and outpatient medical care. It is one of the world's largest integrated providers of products and services for dialysis in patients with chronic kidney failure. Fresenius operates in more than 60 countries, with Europe and North America being its main markets.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Fresenius’ R&D focus on new product and process development, as well as the improvement of therapies. The company's R&D activities are mainly conducted in the Fresenius Kabi business segment, with a focus on generic IV drugs, biopharmaceuticals, infusion and nutrition therapies, and medical devices. In addition to new products, the company is concentrating on developing optimized or completely new therapies, treatment methods, and services. The company also uses research services provided by third parties, especially in the field of biopharmaceuticals. The company is also advancing clinical nutrition, medical devices, and generic IV drugs, with a focus on digitalization, platform technologies, and strategic partnerships to enhance product development In the area of generic IV drugs, the company’s research and development activities focus on developing complex formulations like an emulsion solution that has already been approved as a first-to-file abbreviated new drug application in the US and peptide formulations that can be administered using an autoinjector and other methods. In the field of medical devices, the company prioritizes the development of new products as well as the expansion of its existing portfolio. Digitalization is a significant aspect of the medical industry, requiring devices to be updated to fit into the IT systems of hospitals, blood donation centers, and plasma centers. The company is committed to bringing more therapeutic solutions to more patients in the biopharmaceutical space. The company has main research sites in Europe, the US, and India, with product-related development activities also carried out in China. As of December 31, 2025, the company had 2,532 employees in the research and development department. In FY2025, Fresenius spent EUR624 million on R&D, which as a percentage of revenue stood at 2.7%.